In summary, we successfully developed a novel liver-targeted lentivirus vector system by incorporating a hepatocyte-targeted peptide derived from CSP into the lentivirus envelope for liver-targeted delivery of IDOL-shRNA to specifically inhibit hepatic IDOL expression, thus enabling more potent reduction of hypercholesterolemia and alleviating atherosclerosis. Here, MYLIP is linked to atherosclerosis.